Moderna CFO David Meline to retire by Dec 31, 2022; will serve as consultant through Mar 2026

Moderna, Inc.

David Meline continues as CFO until Dec 31, 2022 (or earlier if successor starts); consulting services to Mar 2, 2026.
Continued vesting in new hire equity award (to July 8, 2024), 2021 annual grant (to July 8, 2024), and 2022 annual grant (to Mar 2, 2026).
Prorated 2022 annual bonus at target; vested stock options extend 12 months after consulting period (not beyond original expiration).
Agreement supersedes April 10, 2022 retirement deal; includes non-disparagement, cooperation, and general release of claims.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Meline

Chief Financial Officer

MRNA · Moderna, Inc.

Effective: 2022-12-31
Filed: June 1, 2022, 7:59 PM ET

Mr. Meline’s continued service as Chief Financial Officer of the Company and his voluntary retirement from the Company on December 31, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Meline retired as Chief Financial Officer at Moderna, Inc..

Action: retired
Role: Chief Financial Officer

Exact text from the filing

Mr. Meline’s continued service as Chief Financial Officer of the Company and his voluntary retirement from the Company on December 31, 2022

View on SEC.gov

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-165220

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.